Replies to post #1664 on Dendreon Corp fka DNDNQ

[i760]

Bull Case --

I-Village post by akasidney86 trumps the bear case. Link:

http://www1.investorvillage.com/smbd.asp?mb=971&mn=14187&pt=msg&mid=832015

[ocyanblue]

<4. Changing the 9902b protocol to make Cox the primary endpoint supports the contention in item #3 above and makes 9902b the real pivotal study, in my view. (I.e., DNDN learned ex post facto that Cox gave a good result in 9902a and hence they are testing this Cox endpoint prospectively in 9902b. This is how things are supposed to be done.)>

This is a truly neat insight. I didn't know that Dendreon does research in biostatistics and is trying to get the FDA approval to sell a that to cure prostate cancer. I always thought that the endpoint for 9902b was survival. This Cox endpoint is something else. I guess we learn something new every day. Thanks Dew.

[io_io]

#4 is particularly, shall we say, a stretch:

<<<"4. Changing the 9902b protocol to make Cox the primary endpoint supports the contention in item #3 above and makes 9902b the real pivotal study, in my view. (I.e., DNDN learned ex post facto that Cox gave a good result in 9902a and hence they are testing this Cox endpoint prospectively in 9902b. This is how things are supposed to be done.)">>>


The "ex post facto" bit is lovely but is 9902b now supposed to be supportive of 9902a ?? Have we forgotten 9901 nailing Survival in terms of the prospectively defined log-rank analysis ?


Or is that all log-ranks in Provenge will be imbalanced in favor of the drug arm ??